Allogene Therapeutics, Inc. (ALLO) Stock Grade

About Allogene Therapeutics, Inc.'s fundamentals

Allogene Therapeutics is a biotech company with a market capitalization of $562.6 million that reported negative revenue growth of -100.0% year-over-year, indicating no reported product revenues in its latest period. The company posted a net loss in its latest annual statement with a net margin of 0.0%, and it does not pay dividends. With traditional profitability metrics unavailable, investors should note that the company's financial performance is characteristic of early-stage biotechnology firms that typically operate at a loss while developing pipeline candidates.